Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $46.00 at JPMorgan Chase & Co.

Olema Pharmaceuticals (NASDAQ:OLMA) had its target price lowered by investment analysts at JPMorgan Chase & Co. from $52.00 to $46.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 340.70% from the company’s previous close.

Other research analysts have also issued research reports about the stock. HC Wainwright decreased their price target on shares of Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday. Weiss Ratings cut Olema Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 3rd. Wall Street Zen downgraded Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th. Citigroup lowered their target price on Olema Pharmaceuticals to $59.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Guggenheim dropped their price target on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.40.

Olema Pharmaceuticals Stock Performance

OLMA stock traded down $0.00 during midday trading on Thursday, reaching $10.44. 345,855 shares of the company were exchanged, compared to its average volume of 1,432,238. Olema Pharmaceuticals has a one year low of $5.15 and a one year high of $36.26. The firm has a market capitalization of $913.33 million, a price-to-earnings ratio of -4.92 and a beta of 2.03. The business has a 50-day moving average price of $11.24 and a two-hundred day moving average price of $15.55. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.06). Equities research analysts forecast that Olema Pharmaceuticals will post -2.22 EPS for the current year.

Insider Buying and Selling at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 12,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total value of $144,750.00. Following the sale, the director owned 715,270 shares in the company, valued at $8,282,826.60. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 12.56% of the company’s stock.

Institutional Trading of Olema Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bain Capital Life Sciences Investors LLC increased its stake in shares of Olema Pharmaceuticals by 24.3% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after buying an additional 1,664,687 shares during the period. Paradigm Biocapital Advisors LP raised its holdings in Olema Pharmaceuticals by 11.0% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock valued at $188,604,000 after buying an additional 750,000 shares during the last quarter. Janus Henderson Group PLC boosted its position in Olema Pharmaceuticals by 5.9% during the 1st quarter. Janus Henderson Group PLC now owns 7,108,488 shares of the company’s stock worth $106,013,000 after buying an additional 398,294 shares during the period. BlackRock Inc. acquired a new stake in Olema Pharmaceuticals during the 2nd quarter worth approximately $84,001,000. Finally, Siren L.L.C. boosted its position in Olema Pharmaceuticals by 44.1% during the 1st quarter. Siren L.L.C. now owns 4,756,949 shares of the company’s stock worth $70,926,000 after buying an additional 1,456,249 shares during the period. 91.78% of the stock is currently owned by institutional investors.

Key Headlines Impacting Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Citigroup maintained a Buy rating and set a $59 price target. Although the target was reduced, it still implies substantial potential upside from recent trading levels. Benzinga analyst price target report
• Positive Sentiment: HC Wainwright also retained its Buy rating and $36 price target, indicating that the firm continues to see longer-term value in Olema’s drug-development pipeline despite near-term losses.
• Neutral Sentiment: Reported short interest was listed at zero shares, meaning the available data does not indicate meaningful short-selling pressure. However, the figures appear inconsistent, limiting their usefulness as a trading signal.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026-2030. Its estimates now call for losses of $2.44 per share in fiscal 2026, $2.78 in 2027, $2.36 in 2028, $1.69 in 2029 and $1.03 in 2030. Quarterly forecasts were also lowered to losses of $0.64 per share in Q3 2026 and $0.67 in Q4. The revisions suggest a slower path toward profitability and are likely weighing on sentiment.
• Negative Sentiment: Olema’s second-quarter loss widened, while its reported quarterly loss of $0.61 per share missed the $0.55 analyst consensus. The disappointing results contributed to a gap-down move in the shares. Olema Pharmaceuticals Q2 Loss Widens
• Negative Sentiment: Recent coverage characterized Citigroup’s outlook as pessimistic, reinforcing concerns about Olema’s valuation and earnings trajectory despite its continued Buy recommendation. Citigroup Issues Pessimistic Forecast for Olema Pharmaceuticals

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.